Compare
Septerna, Inc. vs Protagonist Therapeutics, Inc vs Aquestive Therapeutics, Inc. vs Cumberland Pharmaceuticals Inc
| Latest fiscal year | Septerna, Inc. SEPN | Protagonist Therapeutics, Inc PTGX | Aquestive Therapeutics, Inc. AQST | Cumberland Pharmaceuticals Inc CPIX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $45.95M | $46.02M | $44.55M | $44.52M |
| Revenue growth (YoY) | n/m | -89.4% | -22.6% | +17.6% |
| Gross margin | n/a | n/a | 58.3% (computed) | 85.0% (computed) |
| Operating margin | -148.6% | -343.6% | -159.5% | -6.3% |
| Net margin | -106.4% | -282.8% | -188.1% | -6.4% |
| Net income | -$48.88M | -$130.15M | -$83.78M | -$2.84M |
| EPS (Diluted) | -$1.10 | -$2.05 | -$0.78 | -$0.19 |
| Operating cash flow | $110.19M | $57.67M | -$52.43M | $4.93M |
| Free cash flow | $109.67M | $56.08M | -$52.99M | $4.83M |
| Cash & equivalents | $120.72M | $128.39M | n/a | $11.44M |
| Total assets | $596.19M | $668.19M | $160.43M | $76.82M |
| Total liabilities | $214.26M | $53.48M | $194.09M | $52.28M |
| Shareholders' equity | $381.93M | $614.71M | -$33.66M | $24.88M |
| Return on year-end equity | -12.8% | -21.2% | n/a | -11.4% |
| Shares outstanding | 44.81M | 62.58M | 122.04M | 14.96M |
Revenue, most recent five fiscal years
| Fiscal year | Septerna, Inc. | Protagonist Therapeutics, Inc | Aquestive Therapeutics, Inc. | Cumberland Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $45.95M Ended 2025-12-31 | $46.02M Ended 2025-12-31 | $44.55M Ended 2025-12-31 | $44.52M Ended 2025-12-31 |
| 1 year earlier | $1.07M Ended 2024-12-31 | $434.43M Ended 2024-12-31 | $57.56M Ended 2024-12-31 | $37.87M Ended 2024-12-31 |
| 2 years earlier | $151.0K Ended 2023-12-31 | $60.00M Ended 2023-12-31 | $50.58M Ended 2023-12-31 | $39.55M Ended 2023-12-31 |
| 3 years earlier | n/a | $26.58M Ended 2022-12-31 | $47.68M Ended 2022-12-31 | $42.01M Ended 2022-12-31 |
| 4 years earlier | n/a | $27.36M Ended 2021-12-31 | $50.83M Ended 2021-12-31 | $35.05M Ended 2021-12-31 |